Driscoll one of 40 hospitals nationwide participating in Pfizer trial for COVID-19 vaccine for children younger than 12

Translate to Spanish or other 102 languages!

Iris Gutierrez (from left), Sophia Gutierrez, 10, Pediatrician Valeria Munguia Jovel, MD, Erin Richmond, MS, RN, CCRP, Program Manager, Global Institute for Hispanic Health, and Jaime Fergie, MD, Director of Infectious Diseases at Driscoll Children’s Hospital and Medical Director of Driscoll’s and Texas A&M University’s Global Institute for Hispanic Health.

Mega Doctor News

- Advertisement -

CORPUS CHRISTI – Driscoll Children’s Hospital is one of 40 hospitals nationwide and 100 hospitals worldwide participating in a Pfizer clinical trial for a COVID-19 vaccine for children younger than 12. Driscoll is the only clinical trial site for South Texas.

The first participant, Sophia Gutierrez, 10, of Odem, was at Driscoll on Monday undergoing the necessary labwork and receiving her first shot.

“I really wanted to get vaccinated so I could see my grandmother and other family members,” said Sophia.

- Advertisement -

The clinical trial is open for children six months to 11 years. Driscoll Children’s Hospital and Texas A&M University’s Global Institute for Hispanic Heath are conducting the trial, but participants do not have to be Hispanic or Driscoll patients.

“The Global Institute for Hispanic Health strives to bring important clinical studies to our region. We are happy to be able to offer this COVID-19 trial to the children of South Texas,” said Jaime Fergie, MD, Director of Infectious Diseases at Driscoll Children’s Hospital and Medical Director of Driscoll’s and Texas A&M University’s Global Institute for Hispanic Health.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Small Steps in Weight Loss Lead to Big Heart Health Benefits

When people think about weight loss, they often picture dramatic transformations: a major drop on the scale, a new clothing size or a before-and-after photo. But when it comes to overall health, some of the biggest benefits can begin long before those milestone moments.

FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer  

The U.S. Food and Drug Administration expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment.

Do You Want to Be an Angel? This Is Your Opportunity

Becoming an angel for someone facing cancer may be as simple as donating $3 or $5. Through DHR Health’s annual Bras for a Cause fundraiser, community members can help patients experiencing financial difficulties while supporting breast cancer awareness and early detection.

The Power of Proper Handwashing

One simple habit can go a long way toward helping you stay healthy.
- Advertisement -